 Good morning, everybody. Let me introduce myself and our team. My name is Vladimir Anisimov. I am chief of department of cardiogenesis and oncology at Petrov National Medical Research Center of oncology in St. Petersburg. Professor Zharinov is head of radiology department at Russian National Center Radiology Surgical Technology was opened in 1918. Our institute was opened in 1927. Dr. Bogomolov and Dr. Niklasova were working together with Professor Zharinov. Dr. Cheprunaya was working at St. Petersburg Clinical Scientific and Practical Center for specialized types of medical care. Low picture. It picture of free hour institute. Next couple words about history of our research. In 1961 Dr. Mordechai Schwartz published paper showing the patients died when the tumor reached its critical size. Approximately 10 in certain power. The survival of patients depends on the tumor rate. There are a lot of data on tumor doubling time. Mainly paper devoted to proliferation. But cell loss, which is very important part of the natural history of tumor growth, is much less paper. So in 1989 it was shown for the first time by Dr. Zharinov, that in the patients of cervical cancer patients who have fast growing tumors have less cell loss than people, women who have cervical cancer slowly growing. It is a second paper by Dr. Gennady Zharinov, that our team shown that cell loss plays a principal role in tumor growth. You see, local prostatic cancer have much more cell loss frequency, incomprehensible to metastatic. Баланс-терапия is non-dimagine treatment aimed at maintaining balance between proliferation and cell loss in order to increase the life span of cancer patients. Efficiency of combined treatment of prostatic cancer patients was improved by use of melatonin as an element of balance therapy. Хистерия of melatonin rather short. It was firstly isolated, melatonin was firstly isolated in 1958 by our own learner from Paneo-Gland of Kalf. In 1973 we have shown melatonin in Hibis mammary tumor mice. It was first paper on this matter. In 1974 melatonin was discovered in enterechromatine cells in testines in some other tissue by Igor Kvitnoi. In 1980 it was shown by IFF-2-2 France-Paris. The H-rated declares production secretion of melatonin. Вайтер Перпауле, в 1987, first published paper, The Melatonin increased life span mice. And a writer from San Antonio, Texas, showed melatonin as potent antioxidant. In this picture you can see that melatonin Hibis tumor adgenesis in rodents a lot of size, localization, mammary, cervix, colon, skin, soft, libre, lung. МайорITY was done in our lab. We also study effect of melatonin treatment in stomach cancer and colon cancer patients. Recurrence time was extremely increased by 27% in patients with stomach cancer. Meta-analysis of 10 randomized trials showed decrease in one year mortality up to 0.66 in solid tumor patients. Some illustration of our research. Melatonin sufficiently inhibits colon cancer and adgenesis induced by dimethylgitrazine in rods. It's accomplished by the depletion of mitotic index and stimulation of apoptosis. Tumor incidence was dramatically decreased. Another paper was published in International Journal of Cancer. We have shown the constant elimination increase accelerated the mammary carcinogenesis in transgenic mice. A treatment with melatonin inhibits expression of disengagement at decreased number of tumors, size of tumors and number of tumors per animal. Thus, let me show the design of our study. It was involved 955 patients with prostate cancer which received combined treatment, hormonal radiation, since 2000 up to last year. Тритая группа 396 patients were treated with melatonin. It was around 30 minutes before sleeping, except winter, because winter level of melatonin is good enough. Control group was not treated with melatonin. It was 559 patients. Groups were subdivided according to prognosis. Good prognosis, favorable prognosis, localized prostate cancer. Intermediate prognosis, localized spread. At metastatic prostate cancer it's bad, poor prognosis. It's much maximum number of patients. Main result are shown on this slide. Good prognosis and intermediate prognosis have not strong effect on survival of prostate cancer patients. However, median survival of melatonin treated poor prognosis patients was more than two times higher than in control group. 40, 64 months for control group and 153 months treated with melatonin. We conclude the methods of balanced therapy and improving survival of cancer patients. We plan to continue studying the factors influence the rate of tumor growth proliferation and cell loss in cancer patients. At present we have data on good effect of melatonin in breast cancer in women but melanoma was unsuccessful. Thank you for your attention.